Alice Mohr

922 total citations
14 papers, 627 citations indexed

About

Alice Mohr is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Alice Mohr has authored 14 papers receiving a total of 627 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 7 papers in Oncology. Recurrent topics in Alice Mohr's work include Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Alice Mohr is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (6 papers). Alice Mohr collaborates with scholars based in United States and Canada. Alice Mohr's co-authors include Zale P. Bernstein, Asher Chanan‐Khan, Kena C. Miller, Myron S. Czuczman, Kenichi Takeshita, Paul K. Wallace, Francisco J. Hernandez‐Ilizaliturri, Swaminathan P. Iyer, Laurie Musial and David Lawrence and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Seminars in Oncology.

In The Last Decade

Alice Mohr

13 papers receiving 607 citations

Peers

Alice Mohr

GENET

PFM

HEMAT

ONCOL

Karin E. Summers United Kingdom

Silvia Zibellini Italy

Olga Samoilova Russia

Leanne Holes United States

Emanuele Cencini Italy

Alison Morilla United Kingdom

Nadine Juge‐Morineau France

Christos Karkantaris Greece

Thomas M. Jahn United States

Alice Lynn United States

Karin E. Summers United Kingdom

Alice Mohr

251 ×0.6

GENET

404 ×1.0

PFM

163 ×0.8

HEMAT

280 ×1.5

ONCOL

138 ×0.9

Citations per year, relative to Alice Mohr Alice Mohr (= 1×) peers Karin E. Summers

Countries citing papers authored by Alice Mohr

Since Specialization

Citations

This map shows the geographic impact of Alice Mohr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alice Mohr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alice Mohr more than expected).

Fields of papers citing papers by Alice Mohr

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alice Mohr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alice Mohr. The network helps show where Alice Mohr may publish in the future.

Co-authorship network of co-authors of Alice Mohr

This figure shows the co-authorship network connecting the top 25 collaborators of Alice Mohr. A scholar is included among the top collaborators of Alice Mohr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alice Mohr. Alice Mohr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Chanan‐Khan, Asher, Kena C. Miller, Laurie Musial, et al.. (2009). Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leukemia & lymphoma. 50(7). 1096–1101. 17 indexed citations

Patel, Mehul, Taimur Sher, Sikander Ailawadhi, et al.. (2008). Novel Agents Overcome the Adverse Prognosis Imparted by Compromised Renal Function in Patients with Multiple Myeloma. Blood. 112(11). 2726–2726. 1 indexed citations

Ailawadhi, Sikander, Taimur Sher, Mehul Patel, et al.. (2008). International Staging System (ISS) Is Superior to Durie-Salmon (DS) Staging in Predicting Overall Mortality in Multiple Myeloma (MM). Blood. 112(11). 2745–2745. 1 indexed citations

Czuczman, Myron S., et al.. (2007). Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Clinical Efficacy without Cardiac Toxicity.. Blood. 110(11). 1369–1369.

Miller, Kena C., Alice Mohr, Terry Mashtare, et al.. (2007). Oral Acyclovir Is an Effective in Decreasing the Incidence of Bortezomib Associated Herpes Zoster in Patients with Multiple Myeloma.. Blood. 110(11). 4844–4844. 1 indexed citations

Chanan‐Khan, Asher, Kena C. Miller, Laurie Musial, et al.. (2006). Clinical Efficacy of Lenalidomide in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia: Results of a Phase II Study. Journal of Clinical Oncology. 24(34). 5343–5349. 314 indexed citations

Chanan‐Khan, Asher, Kena C. Miller, Kenichi Takeshita, et al.. (2005). Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL). Blood. 106(10). 3348–3352. 82 indexed citations

Miller, Kena C., M. S. Czuczman, Philip L. McCarthy, et al.. (2005). Antileukemic effects of novel immunomodulatory agent lenalinomide (L) with or without rituximab (R) in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL). Encouraging preliminary results of an ongoing phase II clinical study. Journal of Clinical Oncology. 23(16_suppl). 6557–6557. 8 indexed citations

Czuczman, M. S., Alice Mohr, Kathleen Donohue, et al.. (2005). Rituximab in Combination With Fludarabine Chemotherapy in Low-Grade or Follicular Lymphoma. Journal of Clinical Oncology. 23(4). 694–704. 110 indexed citations

10.

Czuczman, Myron S., Alice Mohr, Zale P. Bernstein, et al.. (2004). Phase I/II Study of Rituxan (R) in Combination with Doxil (D) in Patients (pts) with Relapsing or Refractory B-Cell Lymphoma: Promising Early Results.. Blood. 104(11). 1396–1396. 1 indexed citations

11.

Chanan‐Khan, Asher, Kena C. Miller, Philip L. McCarthy, et al.. (2004). VAD-t (Vincristine, Adriamycin, Dexamethasone and Low-Dose Thalidomide) Is an Effective Initial Therapy with High Response Rates for Patients with Treatment Naive Multiple Myeloma (MM).. Blood. 104(11). 3463–3463. 11 indexed citations

12.

Chanan‐Khan, Asher, Kena C. Miller, Kenichi Takeshita, et al.. (2004). Thalidomide (T) in Combination with Fludarabine (F) as Initial Therapy for Patients (pts) with Treatment Naive Chronic Lymphocytic Leukemia (CLL): Results of a Phase I Trial.. Blood. 104(11). 3476–3476. 1 indexed citations

13.

Czuczman, Myron S., Alice Mohr, Carleton C. Stewart, et al.. (2002). Rituximab in combination with CHOP or fludarabine in low-grade lymphoma. Seminars in Oncology. 29(1). 36–40. 79 indexed citations

14.

Dwyer, Sonya Corbin, et al.. (2000). Looking at Metacognitive Learning Strategies Using a Developmental Lens.. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact